Personalized Discharge Letters to Improve Care in Adults with Low-Risk Skin Cancer After Dermatology Screening

What this Trial Is About

Researchers are evaluating a new approach to support low-risk skin cancer patients after dermatological screening by providing personalized discharge letters. These letters combine evidence-based guidelines with details tailored to each patients risk profile, aiming to improve patient understanding, reassurance, and self-care compared to the usual general verbal advice. The study is a prospective, randomized controlled trial comparing different methods of aftercare communication. Participants will be randomly assigned to one of three groups Group A receives standard verbal information only Group B receives a personalized discharge letter customized to their individual risk, skin type, and consultation findings and Group C receives the personalized letter plus digital visual support such as annotated images and visual summaries. The personalized letters are generated by an AI agent trained on validated hospital records and reviewed by a physician before being given to patients. During the study, participants levels of reassurance, knowledge about their personal skin cancer risk, and confidence in performing self-skin checks will be measured immediately after consultation and followed for about one year. Researchers will assess how these different communication approaches affect patient understanding and self-management. The study will continue until June 2029, with data collected through questionnaires and follow-ups related to the aftercare experience.

CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients